Literature DB >> 17291377

The burden of parvovirus B19 infection in women of childbearing age in England and Wales.

A J Vyse1, N J Andrews, L M Hesketh, R Pebody.   

Abstract

A serological survey has been used to investigate the epidemiology of parvovirus B19 infection in England and Wales. A total of 2835 sera representing the complete age range were selected from a convenience collection obtained in 1996 that reflects the general population and screened for parvovirus B19-specific IgG. Antibody prevalence rose nonlinearly with age from 21% in those aged 1-4 years to >75% in adults aged > or = 45 years. Force-of-infection estimates were similar to those previously made in 1991, being highest in those aged <15 years. There was no association between evidence of previous infection and sex or region. Quantitatively strongest antibody responses were found in those aged 15-34 years and IgG levels in females were 28.5% higher than those found in males (P=0.004, 95% CI 8.2-52.6). Applying the upper 95% confidence interval for the force of infection to maternity estimates for England and Wales in 1996, parvovirus infection in pregnancy was estimated to occur on average in up to 1 in every 512 pregnancies each year. This represents 1257 maternal infections, causing up to an estimated 59 fetal deaths and 11 cases of hydrops fetalis annually. An analysis of all available laboratory-confirmed parvovirus infections found a mean of 944 infections per year in women aged 15-44 years highlighting a need for enhanced surveillance of maternal parvovirus B19 infection in England and Wales, including information on both pregnancy and outcome of pregnancy.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17291377      PMCID: PMC2870696          DOI: 10.1017/S0950268807007856

Source DB:  PubMed          Journal:  Epidemiol Infect        ISSN: 0950-2688            Impact factor:   2.451


  15 in total

1.  Ten years of serological surveillance in England and Wales: methods, results, implications and action.

Authors:  K Osborne; N Gay; L Hesketh; P Morgan-Capner; E Miller
Journal:  Int J Epidemiol       Date:  2000-04       Impact factor: 7.196

2.  A random cluster survey and a convenience sample give comparable estimates of immunity to vaccine preventable diseases in children of school age in Victoria, Australia.

Authors:  Heath Kelly; Michaela A Riddell; Heather F Gidding; Terry Nolan; Gwendolyn L Gilbert
Journal:  Vaccine       Date:  2002-08-19       Impact factor: 3.641

3.  Improving sensitivity of oral fluid testing in IgG prevalence studies: application of mixture models to a rubella antibody survey.

Authors:  N J Gay; A J Vyse; F Enquselassie; W Nigatu; D J Nokes
Journal:  Epidemiol Infect       Date:  2003-04       Impact factor: 2.451

4.  Interpreting serological surveys using mixture models: the seroepidemiology of measles, mumps and rubella in England and Wales at the beginning of the 21st century.

Authors:  A J Vyse; N J Gay; L M Hesketh; R Pebody; P Morgan-Capner; E Miller
Journal:  Epidemiol Infect       Date:  2006-05-02       Impact factor: 2.451

5.  The prevalence of antibody to human parvovirus B19 in England and Wales.

Authors:  B J Cohen; M M Buckley
Journal:  J Med Microbiol       Date:  1988-02       Impact factor: 2.472

6.  Prospective study of human parvovirus (B19) infection in pregnancy. Public Health Laboratory Service Working Party on Fifth Disease.

Authors: 
Journal:  BMJ       Date:  1990-05-05

7.  Clinical manifestations of human parvovirus B19 in adults.

Authors:  A D Woolf; G V Campion; A Chishick; S Wise; B J Cohen; P T Klouda; O Caul; P A Dieppe
Journal:  Arch Intern Med       Date:  1989-05

8.  Female children respond to recombinant hepatitis B vaccine with a higher titre than male.

Authors:  J W Fang; C L Lai; H T Chung; P C Wu; J Y Lau
Journal:  J Trop Pediatr       Date:  1994-04       Impact factor: 1.165

9.  Sex differences in response to hepatitis B virus. I. History.

Authors:  B S Blumberg
Journal:  Arthritis Rheum       Date:  1979-11

10.  Age specific antibody prevalence to parvovirus B19: how many women are infected in pregnancy?

Authors:  N J Gay; L M Hesketh; B J Cohen; M Rush; C Bates; P Morgan-Capner; E Miller
Journal:  Commun Dis Rep CDR Rev       Date:  1994-08-19
View more
  15 in total

Review 1.  Parvovirus B19 infection in human pregnancy.

Authors:  R F Lamont; J D Sobel; E Vaisbuch; J P Kusanovic; S Mazaki-Tovi; S K Kim; N Uldbjerg; R Romero
Journal:  BJOG       Date:  2010-10-13       Impact factor: 6.531

2.  Seroprevalence of antibodies against serogroup C meningococci in England in the postvaccination era.

Authors:  Caroline L Trotter; Ray Borrow; Jamie Findlow; Ann Holland; Sarah Frankland; Nick J Andrews; Elizabeth Miller
Journal:  Clin Vaccine Immunol       Date:  2008-09-30

3.  Widespread infection with homologues of human parvoviruses B19, PARV4, and human bocavirus of chimpanzees and gorillas in the wild.

Authors:  Colin P Sharp; Matthew LeBreton; Kalle Kantola; Ahmadou Nana; Joseph Le Doux Diffo; Cyrille F Djoko; Ubald Tamoufe; John A Kiyang; Tafon G Babila; Eitel Mpoudi Ngole; Oliver G Pybus; Eric Delwart; Eric Delaporte; Martine Peeters; Maria Soderlund-Venermo; Klaus Hedman; Nathan D Wolfe; Peter Simmonds
Journal:  J Virol       Date:  2010-07-28       Impact factor: 5.103

4.  Occupational risk of human Cytomegalovirus and Parvovirus B19 infection in female day care personnel in the Netherlands; a study based on seroprevalence.

Authors:  F F Stelma; A Smismans; V J Goossens; C A Bruggeman; C J P A Hoebe
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2008-10-11       Impact factor: 3.267

5.  High frequencies of exposure to the novel human parvovirus PARV4 in hemophiliacs and injection drug users, as detected by a serological assay for PARV4 antibodies.

Authors:  Colin P Sharp; Alice Lail; Sharyne Donfield; Ruth Simmons; Clifford Leen; Paul Klenerman; Eric Delwart; Edward D Gomperts; Peter Simmonds
Journal:  J Infect Dis       Date:  2009-10-01       Impact factor: 5.226

6.  Rapid sequence change and geographical spread of human parvovirus B19: comparison of B19 virus evolution in acute and persistent infections.

Authors:  Päivi Norja; Anna Maria Eis-Hübinger; Maria Söderlund-Venermo; Klaus Hedman; Peter Simmonds
Journal:  J Virol       Date:  2008-04-16       Impact factor: 5.103

7.  Seroprevalence of parvovirus B19 in the German population.

Authors:  C Röhrer; B Gärtner; A Sauerbrei; S Böhm; B Hottenträger; U Raab; W Thierfelder; P Wutzler; S Modrow
Journal:  Epidemiol Infect       Date:  2008-01-16       Impact factor: 2.451

8.  Model structure analysis to estimate basic immunological processes and maternal risk for parvovirus B19.

Authors:  Nele Goeyvaerts; Niel Hens; Marc Aerts; Philippe Beutels
Journal:  Biostatistics       Date:  2010-09-14       Impact factor: 5.899

9.  The seroprevalence of parvovirus B19 infection in pregnant women in Sudan.

Authors:  O Adam; T Makkawi; U Reber; H Kirberg; A M Eis-Hübinger
Journal:  Epidemiol Infect       Date:  2014-03-20       Impact factor: 4.434

10.  Parenteral transmission of the novel human parvovirus PARV4.

Authors:  Peter Simmonds; Ashleigh Manning; Rachel Kenneil; Frances W Carnie; Jeanne E Bell
Journal:  Emerg Infect Dis       Date:  2007-09       Impact factor: 6.883

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.